Novo Nordisk shares plunge as obesity drug trails Eli Lilly in clinical trial
Novo Nordisk shares fell eleven percent today after its weight loss drug CagriSema failed to outperform Eli Lillys tirzepatide in a major head to head study.
Insights:
Novo Nordisk A/S announced today that its next-generation obesity drug, CagriSema, failed to demonstrate non-inferiority to Eli Lilly and Company 's tirzepatide in a head-to-head clinical trial. The study revealed that CagriSema achieved a mean body-weight reduction of 23% over 84 weeks, compared to a 25.5% reduction for tirzepatide. This outcome meant the trial failed to meet its primary goal of showing that CagriSema was at least as effective as its competitor in reducing weight.
